Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 10/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 7/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20179280 | 1.00 | S1PR5 (0.37) | S1PR5S1PR4ALOX5KDM4EMEN1 | |
| SCHEMBL20174520 | 0.93 | S1PR5 (0.37) | S1PR5S1PR4ALOX5KDM4EALDH1A1 | |
| SCHEMBL20174462 | 0.92 | KDM4E (0.34) | S1PR5S1PR4ALOX5KDM4EALDH1A1 | |
| SCHEMBL20174495 | 0.91 | CYP1A1 (0.38) | S1PR5S1PR4KDM4EMEN1ALDH1A1 | |
| SCHEMBL20174445 | 0.91 | MEN1 (0.34) | ALOX5KDM4EMEN1ALDH1A1TP53 | |
| SCHEMBL22326533 | 0.91 | MEN1 (0.34) | ALOX5KDM4EMEN1ALDH1A1TP53 | |
| SCHEMBL20174467 | 0.90 | PDK2 (0.34) | ALOX5KDM4EMEN1ALDH1A1TP53 | |
| SCHEMBL20174502 | 0.89 | CYP1A1 (0.39) | S1PR5S1PR4KDM4EMEN1ALDH1A1 | |
| SCHEMBL20174491 | 0.88 | S1PR5 (0.37) | S1PR5S1PR4ALOX5KDM4EMEN1 | |
| SCHEMBL20174528 | 0.88 | PDK2 (0.36) | ALOX5KDM4EMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738034-B2 | Spiro compound and organic light-emitting device comprising same | LG CHEM, LTD. (KR) | 2020-08-11 | — | — | US | disclosed |
| US-20180141933-A1 | SPIRO COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-05-24 | — | — | US | disclosed |
| US-20180141933-A1 | SPIRO COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738034-B2 | Spiro compound and organic light-emitting device comprising same | CRY1, NR2E3, ERG | S1PR5 3034/4885S1PR4 1783/4885ALOX5 2705/4885 |
| US-20180141933-A1 | SPIRO COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | CRY1, NR2E3, ERG | S1PR5 3034/4885S1PR4 1783/4885ALOX5 2705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.